NCT03089333View on ClinicalTrials.gov

Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects

PHASE4CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

October 31, 2017

Study Completion Date

December 31, 2017

Conditions
HypertensionDiabetes Mellitus, Type 2Blood PressureObesityCardiac HypertrophyMicroalbuminuriaVascular Stiffness
Interventions
DRUG

Dapagliflozin 10mg

Dapagliflozin at a dose of 10mg daily in combination with metoformin and current antihypertensive therapy for 12 weeks

DRUG

Glibenclamide 5Mg Tablet

Glibenclamide at a dose of 5mg daily in combination with metoformin and current antihypertensive therapy for 12 weeks

Trial Locations (1)

13083970

University of Campinas (UNICAMP), Campinas

All Listed Sponsors
collaborator

Fundação de Amparo à Pesquisa do Estado de São Paulo

OTHER_GOV

lead

University of Campinas, Brazil

OTHER

NCT03089333 - Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects | Biotech Hunter | Biotech Hunter